Management Presentation: Biosimilar Pipeline and Margin Improvement Strategy

A broad portfolio generating USD 9.1bn in sales Net sales by business FY 2022, in USD Generics 7.1bn +3% 1 79% SANDOZ 9.1bn +4%1 21% One of the broadest Generics portfolios in the industry Biosimilars 1.9bn +9% 1 8 in-market Biosimilar products Increasing contribution from Biosimilars Note: Net sales to third parties based on unaudited carve-out financials extract. Numbers may not add up due to rounding; 1. Growth vs. 2021 in constant currencies. For additional information regarding constant currencies, which is a non-IFRS measure, see "Appendix" starting on slide 31. 7 Management Presentation SANDOZ

View entire presentation